Bright Minds Biosciences (DRUG) Common Equity (2020 - 2026)

Bright Minds Biosciences' Common Equity history runs 7 years deep, the most recent figure standing at $225.0 million for Q1 2026.

• Quarterly Common Equity rose 479.14% year-over-year to $225.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $225.0 million (up 479.14% YoY) and the FY2025 annual result came in at $59.6 million, up 1368.96% from the prior year.
• Common Equity was $225.0 million for Q1 2026 at Bright Minds Biosciences, up from $64.0 million in the prior quarter.
• Across five years, Common Equity topped out at $225.0 million in Q1 2026 and bottomed at $4.1 million in Q3 2024.
• A 5-year average of $31.3 million and a median of $8.1 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity slumped 62.86% — and 2025, when it jumped 1368.96%.
• Bright Minds Biosciences' Common Equity stood at $8.1 million in 2022, then slumped by 45.15% to $4.4 million in 2023, then soared by 834.14% to $41.4 million in 2024, then soared by 54.66% to $64.0 million in 2025, then surged by 251.42% to $225.0 million in 2026.
• Business Quant data shows DRUG's Common Equity at $225.0 million in Q1 2026, $64.0 million in Q4 2025, and $59.6 million in Q3 2025.